Zocitab
Capecitabine tablets for metastatic breast and colorectal cancer. The body converts it into the active chemotherapy agent inside the tumour.
- Categories
- Women's Health · Oncology Support
- Active ingredient
- Capecitabine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 500mg
Prescription and consultation requirements for Zocitab vary by destination and are determined by the fulfilment partner.
Zocitab details
- Conditions
- Metastatic Breast Cancer · Colorectal Cancer
- Alternative names
- capecitabine
- Therapeutic class
- Fluoropyrimidine Carbamate
- Pharmacological class
- Antineoplastic
- Known off-label uses
- gastric cancer
- Contraindications
- severe renal impairment; known dihydropyrimidine dehydrogenase (DPD) deficiency
- Minor side effects
- nausea; diarrhoea; vomiting
- Moderate side effects
- hand-foot syndrome; fatigue; myelosuppression
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Fresenius Kabi
- Onset Time
- 2–4 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store below 25°C. Keep dry.
- Drug interactions
- Warfarin; Phenytoin; Leucovorin
- Age restrictions
- Approved for adults.
Serious side effects
severe cardiotoxicity, requires immediate medical attention; severe diarrhoea with dehydration, requires immediate medical attention
Patient summary
Capecitabine tablets for metastatic breast and colorectal cancer. The body converts it into the active chemotherapy agent inside the tumour.
Mechanism of action
Enzymatically converts to 5-fluorouracil in tumour cells, inhibiting thymidylate synthase to block DNA synthesis.
Pregnancy and breastfeeding
Pregnancy: High risk of fetal toxicity. Strictly contraindicated in pregnancy. Breastfeeding: Contraindicated.